[14C] AZD8931 - A Phase I, Open Label Study of the Absorption, Metabolism, Excretion, and Pharmacokinetics Following a Single Oral Dose to Healthy Male Subjects
Phase of Trial: Phase I
Latest Information Update: 10 Oct 2014
At a glance
- Drugs Sapitinib (Primary)
- Indications Solid tumours
- Focus Pharmacokinetics
- Sponsors AstraZeneca
- 20 Jun 2011 Actual end date (May 2011) added as reported by ClinicalTrials.gov.
- 20 Jun 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 29 Mar 2011 Actual initiation date (Mar 2011) added as reported by ClinicalTrials.gov.